

# Revcovi® (elapegademase-lvlr) is now part of the Chiesi Global Rare Diseases portfolio

Dear Payer,

Chiesi Global Rare Diseases is pleased to announce the addition of Revcovi® (elapegademase-lvlr); an enzyme replacement therapy indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients, to its portfolio.

The acquisition of Revcovi supports Chiesi Global Rare Diseases' commitment to address significant areas of unmet need in the treatment of rare diseases.

We are proud to continue providing this option to patients living with ADA-SCID around the world. Effective July 1, 2021, Revcovi will be exclusively available through Eversana Life Sciences Specialty Pharmacy.

Product description	NDC #	Strength	Package size
Revcovi® (elapegademase-lvlr) injection 2.4 mg/1.5 mL (1.6 mg/mL)	NDC 57665-002-01	1.6 mg/mL	Single use vial

## INDICATION

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

## IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

## ADVERSE REACTIONS

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:

- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
- Lymphomas

## IMPORTANT MONITORING INFORMATION

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

**Please refer to Revcovi's full Prescribing Information.**

1. Revcovi® (elapegademase-lvlr) Prescribing Information. Chiesi USA Inc., 2021.

For more information contact:		
<p><b>Your Chiesi Rare Disease National Account Director:</b> 1-919-678-6611 us.contact@chiesi.com</p>	<p><b>Eversana</b> (Via Chiesi Total Care<sup>SM</sup>) chiesitotalcare.com 1-866-272-7078 Fax: 1-866-272-7079</p>	<p><b>Or visit</b> <b>revcovi.com</b></p>